PMID

Data

Article Title

Organization

Carbamazepine derivatives with P2X4 receptor-blocking activity.

University of Bonn

Synthesis and structure-activity relationships of suramin-derived P2Y11 receptor antagonists with nanomolar potency.

University of Bonn

Discovery and optimization of RO-85, a novel drug-like, potent, and selective P2X3 receptor antagonist.

Roche Palo Alto

N-substituted phenoxazine and acridone derivatives: structure-activity relationships of potent P2X4 receptor antagonists.

University of Bonn

Discovery of potent competitive antagonists and positive modulators of the P2X2 receptor.

University of Bonn

A-803467, a potent and selective Nav1.8 sodium channel blocker, attenuates neuropathic and inflammatory pain in the rat.

Abbott Laboratories

Purine and pyrimidine (P2) receptors as drug targets.

National Institute of Diabetes

Identification and SAR of novel diaminopyrimidines. Part 1: The discovery of RO-4, a dual P2X(3)/P2X(2/3) antagonist for the treatment of pain.

Roche Palo Alto

Identification and SAR of novel diaminopyrimidines. Part 2: The discovery of RO-51, a potent and selective, dual P2X(3)/P2X(2/3) antagonist for the treatment of pain.

Roche Palo Alto

Therapeutic potentials and structure-activity relationship of 1,3-benzodioxole N-carbamothioyl carboxamide derivatives as selective and potent antagonists of P2X4 and P2X7 receptors.

Comsats University Islamabad

Design and synthesis of adamantane-1-carbonyl thiourea derivatives as potent and selective inhibitors of h-P2X4 and h-P2X7 receptors: An Emerging therapeutic tool for treatment of inflammation and neurological disorders.

Comsats University Islamabad

Discovery and synthesis of a novel and selective drug-like P2X(1) antagonist.

Roche Palo Alto

Unveiling the Structure-Activity Relationships at the Orthosteric Binding Site of P2X Ion Channels: The Route to Selectivity.

European Institute For Molecular Imaging (Eimi)

Discovery of 5-methyl-1H-benzo[d]imidazole derivatives as novel P2X3 Receptor antagonists.

Gwangju Institute of Science and Technology (Gist)

Structure-Activity Relationship and Neuroprotective Activity of 1,5-Dihydro-2

National Institute of Diabetes and Digestive and Kidney Diseases

Discovery of clinical candidate Sivopixant (S-600918): Lead optimization of dioxotriazine derivatives as selective P2X3 receptor antagonists.

Shionogi

Dioxotriazine derivatives as a new class of P2X

Shionogi

Structure-activity relationships of pyridoxal phosphate derivatives as potent and selective antagonists of P2X1 receptors.

National Institute of Diabetes and Digestive and Kidney Diseases

Discovery and Structure Relationships of Salicylanilide Derivatives as Potent, Non-acidic P2X1 Receptor Antagonists.

University of Bonn

Potent Suppressive Effects of 1-Piperidinylimidazole Based Novel P2X7 Receptor Antagonists on Cancer Cell Migration and Invasion.

Gwangju Institute of Science and Technology (Gist)

Investigation on 2',3'-

University of Camerino

New P2X3 receptor antagonists. Part 1: Discovery and optimization of tricyclic compounds.

Gedeon Richter

Pyrrolinone derivatives as a new class of P2X3 receptor antagonists Part 2: Discovery of orally bioavailable compounds.

Shionogi

Discovery and Characterization of the Potent and Selective P2X4 Inhibitor

Bayer

Novel Series of Dihydropyridinone P2X7 Receptor Antagonists.

Hoffmann-La Roche

Synthesis and structure-activity relationships of quinolinone and quinoline-based P2X7 receptor antagonists and their anti-sphere formation activities in glioblastoma cells.

Gwangju Institute of Science and Technology (Gist)

Pyrrolinone derivatives as a new class of P2X3 receptor antagonists. Part 1: Initial structure-activity relationship studies of a hit from a high throughput screening.

Shionogi

Synthesis of bicyclic molecular scaffolds (BTAa): an investigation towards new selective MMP-12 inhibitors.

University of Florence

Lead identification to generate 3-cyanoquinoline inhibitors of insulin-like growth factor receptor (IGF-1R) for potential use in cancer treatment.

Wyeth Research